HALO Halozyme Therapeutics Inc.

17.98
+0.29  (+2%)
Previous Close 17.69
Open 18.13
Price To Book 27.24
Market Cap 2,482,487,992
Shares 138,069,410
Volume 939,040
Short Ratio
Av. Daily Volume 1,904,382
Stock charts supplied by TradingView

NewsSee all news

  1. Halozyme Announces Change Of Location Of Annual Stockholders' Meeting

    SAN DIEGO, April 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to support the health and

  2. Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference

    SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will be presenting at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at 11:20 a.m. ET / 8:20 a.m. PT in

  3. Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

    SAN DIEGO, Feb. 25, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech, a member

  4. Halozyme Reports Fourth Quarter and Full Year 2019 Results

    SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its recent

  5. Halozyme Announces CFO Transition

    SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that Elaine D. Sun has been appointed senior vice president and chief financial officer, effective March 2, 2020. Ms. Sun

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 data November 4, 2019 did not meet primary endpoint.
HALO-301
Pancreatic cancer
Approved September 12, 2014.
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
PDUFA date October 18, 2020.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.
PEGPH20 and atezolizumab
Cholangiocarcinoma
Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab) and PEGPH20
Pancreatic cancer
FDA approval announced February 28, 2019.
Trastuzumab (Herceptin) using ENHANZE
Breast cancer
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Phase 1 trial to commence 1Q 2020 with data due 4Q 2020.
ARGX-117
Autoimmune diseases

Latest News

  1. Halozyme Announces Change Of Location Of Annual Stockholders' Meeting

    SAN DIEGO, April 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to support the health and

  2. Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference

    SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will be presenting at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4 at 11:20 a.m. ET / 8:20 a.m. PT in

  3. Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

    SAN DIEGO, Feb. 25, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech, a member

  4. Halozyme Reports Fourth Quarter and Full Year 2019 Results

    SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its recent

  5. Halozyme Announces CFO Transition

    SAN DIEGO, Feb. 24, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that Elaine D. Sun has been appointed senior vice president and chief financial officer, effective March 2, 2020. Ms. Sun

  6. Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call

    SAN DIEGO, Feb. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at 4:30 p.m. ET / 1:30 p.m. PT. Dr.

  7. Halozyme Provides 2020 Business Update And Financial Guidance

    SAN DIEGO, Jan. 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today provided an update on its outlook for 2020, including financial guidance. "We have made tremendous progress repositioning the

  8. Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference

    SAN DIEGO, Jan. 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 8:30 a.m. PT / 11:30

  9. Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium

    SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be

  10. Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of

  11. Bernadette Connaughton Appointed to Syneos Health Board of Directors

    MORRISVILLE, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial

  12. Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it

  13. Halozyme Reports Third Quarter 2019 Results

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its recent corporate activities

  14. Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE® drug delivery technology. In order

  15. Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment

  16. Halozyme To Participate In 2019 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor Global Healthcare

  17. Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology

    SAN DIEGO, Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study